AW
Alpha Wave
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Sep 18, 2026
Alpha Wave is the investment-manager name used in the covered financings and connected to Alpha Wave Global’s official press and investment records.
Recorded funding activity
The recorded activity includes a lead role in Moonwalk Biosciences’ Series B for medicines targeting fat-tissue pathways in obesity and cardiometabolic disease. Other announcements concern AdvanCell’s targeted alpha radiopharmaceuticals for cancer and Ultrahuman’s wearable ring and health-testing products. These events describe the activity captured here rather than the manager’s complete allocation.
- Rounds participated in
- 0
- Confirmed lead rounds
- — All roles disclosed
- New companies
- 0 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share
By stage
No activity in this selection.
By primary sector
No activity in this selection.
By country
No activity in this selection.
Rounds
0 in this selectionNo rounds match this selection.